Introduction: Mantle cell lymphoma (MCL) is a B‐cell neoplasm with CCND1[t(11;14)(q13;q32), cyclin D1] translocation (1). In the guidelines recommend various treatment recommendation based on the age, performance status (fitnes status), comorbities (2). In this retrospective study, we...
lymphoma is nuclear expression of cyclin D1 as a result of an underlying chromosomal translocation involving IGH and CCND1 [t(11;14)] (see Mantle Cell Lymphoma of the Gastrointestinal Tract, Chapter 5, and Mantle Cell Lymphoma, Chapter 13, for additional information on mantle cell lymphoma)....
Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. MCL represents 2-10% of all non-Hodgkin lymphomas. Clinical presentation The male-to-female ratio in ...
Mantle cell lymphoma (MCL) is a rare form of B-cell non-Hodgkin lymphoma (NHL). It is a type of blood cancer that affects white blood cells called lymphocytes. Lymphocytes are white blood cells which help fight infections and other disease...
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and availa
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and available treatments for MCL, this cancer ...
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma–a Nordic lymphoma group study. Br J Haematol. 2014;166(1):98–108. 9. Geisler CH, Kolstad A, Laurell A, et al. The mantle cell lymphoma international prognostic index (MIPI) is ...
Bruton’s tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but intrinsic or acquired resistance inevitably develops. In this study, we assessed the efficacy of the highly potent and selective MCL-1 inhibi...
Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin’s lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous stem cell transplant for the fit, transplant
Mantle cell lymphoma (MCL) is no longer a hopeless disease. Considered to carry a uniformly dismal prognosis so far, during the last years it has been rediscovered as a heterogeneous clinical and biological entity. Such a complexity has been highlighted